Loading…
Pharmaceuticals · NSE · period ending 2026-03-31
Loading chart…
✓ Core business is permissible and non-compliant income is 3.76% of revenue (limit 5%).
| Ratio | Value | Limit | Result |
|---|---|---|---|
| Debt / 36-month avg market cap | 0% | < 33% | Pass |
| Cash + interest-bearing securities / 36-month avg market cap | 3.87% | < 33% | Pass |
| Accounts receivable / 36-month avg market cap | 0.76% | < 33% | Pass |
The underlying figures and the filing citations they came from are available with a free account.
Sign up free3.76% of any dividend from GLAXO should be given to charity. Calculate your amount →
Compliance watch: verdict re-verified against live market cap on 13 Jun 2026 · rechecked every 6 hours · filings reviewed quarterly.
The stock has declined steadily over 1–6 months, sits far below its 52-week high, and has the 50-day below the 200-day. Low-to-moderate volatility underscores a persistent, grinding downtrend.
Computed from delayed price history and desk sentiment. Educational context only — not investment advice or a price prediction.